Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia

Journal of Immunology

Volumn 186, Issue 10, 2011, Pages 6024-6034

  Zhou, Cissy Chenyi ^a   Irani, Roxanna A ^a   Dai, Yingbo ^a,b   Blackwell, Sean C ^a   Hicks, M John ^c   Ramin, Susan M ^a   Kellems, Rodney E ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; CD31 ANTIGEN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOGLIN; ENDOTHELIN 1; IMMUNOGLOBULIN G; INTERLEUKIN 6; MESSENGER RNA; PREPROENDOTHELIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOPATHOGENESIS; KIDNEY; KIDNEY INJURY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PROTEINURIA; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; KIDNEY; MICE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956218173     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004026     Document Type: Article

References (78)

1. Redman, C. W., and I. L. Sargent. 2005. Latest advances in understanding preeclampsia. Science 308: 1592-1594.
2. Roberts, J. M., and D. W. Cooper. 2001. Pathogenesis and genetics of preeclampsia. Lancet 357: 53-56.
3. Granger, J. P., B. T. Alexander, M. T. Llinas, W. A. Bennett, and R. A. Khalil. 2002. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9: 147-160.
4. Godfrey, K. M., and D. J. Barker. 2000. Fetal nutrition and adult disease. Am. J. Clin. Nutr. 71(5, Suppl.)1344S-1352S.
5. Godfrey, K. M., and D. J. Barker. 2001. Fetal programming and adult health. Public Health Nutr. 4(2B): 611-624.
6. Fu, M. L., P. S. Leung, G. Wallukat, G. Bergström, H. Fu, W. Schulze, and H. Herlitz. 1999. Agonist-like activity of antibodies to angiotensin II receptor subtype 1 (AT1) from rats immunized with AT1 receptor peptide. Blood Press. 8: 317-324. (Pubitemid 30220296)
7. Dechend, R., V. Homuth, G. Wallukat, J. Kreuzer, J. K. Park, J. Theuer, A. Juepner, D. C. Gulba, N. Mackman, H. Haller, and F. C. Luft. 2000. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 101: 2382-2387.
8. Zhou, C. C., S. Ahmad, T. Mi, S. Abbasi, L. Xia, M. C. Day, S. M. Ramin, A. Ahmed, R. E. Kellems, and Y. Xia. 2008. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51: 1010-1019. (Pubitemid 351398948)
9. Lavoie, J. L., R. A. Bianco, K. Sakai, H. L. Keen, M. J. Ryan, and C. D. Sigmund. 2004. Transgenic mice for studies of the renin-angiotensin system in hypertension. Acta Physiol. Scand. 181: 571-577.
10. Huppertz, B., J. Kingdom, I. Caniggia, G. Desoye, S. Black, H. Korr, and P. Kaufmann. 2003. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 24: 181-190. (Pubitemid 37184714)
11. Dechend, R., C. Viedt, D. N. Müller, B. Ugele, R. P. Brandes, G. Wallukat, J. K. Park, J. Janke, P. Barta, J. Theuer, et al. 2003. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632-1639. (Pubitemid 36401560)
12. Bobst, S. M., M. C. Day, L. C. Gilstrap, III, Y. Xia, and R. E. Kellems. 2005. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens. 18: 330-336.
13. Siddiqui, A. H., R. A. Irani, S. C. Blackwell, S. M. Ramin, R. E. Kellems, and Y. Xia. 2010. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 55: 386-393.
14. Saito, S., A. Shiozaki, A. Nakashima, M. Sakai, and Y. Sasaki. 2007. The role of the immune system in preeclampsia. Mol. Aspects Med. 28: 192-209.
15. Dekker, G. A., and B. M. Sibai. 1998. Etiology and pathogenesis of preeclampsia: current concepts. Am. J. Obstet. Gynecol. 179: 1359-1375.
16. Sargent, I. L., S. J. Germain, G. P. Sacks, S. Kumar, and C. W. Redman. 2003. Trophoblast deportation and the maternal inflammatory response in preeclampsia. J. Reprod. Immunol. 59: 153-160.
17. Borzychowski, A. M., I. L. Sargent, and C. W. Redman. 2006. Inflammation and pre-eclampsia. Semin. Fetal Neonatal Med. 11: 309-316.
18. Meekins, J. W., P. J. McLaughlin, D. C. West, I. R. McFadyen, and P. M. Johnson. 1994. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin. Exp. Immunol. 98: 110-114.
19. Vince, G. S., P. M. Starkey, R. Austgulen, D. Kwiatkowski, and C. W. Redman. 1995. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br. J. Obstet. Gynaecol. 102: 20-25.
20. Visser, W., I. Beckmann, H. A. Bremer, H. L. Lim, and H. C. Wallenburg. 1994. Bioactive tumour necrosis factor alpha in pre-eclamptic patients with and without the HELLP syndrome. Br. J. Obstet. Gynaecol. 101: 1081-1082.
21. Wang, Y., D. F. Lewis, Y. Gu, S. Zhao, and L. J. Groome. 2011. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 57: 336-342.
22. Dahm, P., D. S. Rao, and C. F. Donatucci. 2002. Antiandrogens in the treatment of priapism. Urology 59: 138.
23. Irani, R. A., Y. Zhang, C. C. Zhou, S. C. Blackwell, M. J. Hicks, S. M. Ramin, R. E. Kellems, and Y. Xia. 2010. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension 55: 1246-1253.
24. Taylor, R. N., M. Varma, N. N. Teng, and J. M. Roberts. 1990. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol. Metab. 71: 1675-1677.
25. Nova, A., B. M. Sibai, J. R. Barton, B. M. Mercer, and M. D. Mitchell. 1991. Maternal plasma level of endothelin is increased in preeclampsia. Am. J. Obstet. Gynecol. 165: 724-727.
26. Clark, B. A., L. Halvorson, B. Sachs, and F. H. Epstein. 1992. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am. J. Obstet. Gynecol. 166: 962-968.
27. Dekker, G. A., A. A. Kraayenbrink, G. G. Zeeman, and G. J. van Kamp. 1991. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 40: 215-220.
28. Kraayenbrink, A. A., G. A. Dekker, G. J. van Kamp, and H. P. van Geijn. 1993. Endothelial vasoactive mediators in preeclampsia. Am. J. Obstet. Gynecol. 169: 160-165.
29. Mastrogiannis, D. S., W. F. O'Brien, J. Krammer, and R. Benoit. 1991. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am. J. Obstet. Gynecol. 165: 1711-1716.
30. Bernardi, F., L. Constantino, R. Machado, F. Petronilho, and F. Dal-Pizzol. 2008. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in preeclamptic women. J. Obstet. Gynaecol. Res. 34: 957-963.
31. Ariza, A. C., N. A. Bobadilla, and A. Halhali. 2007. [Endothelin 1 and angiotensin II in preeeclampsia]. Rev. Invest. Clin. 59: 48-56.
32. Aydin, S., A. Benian, R. Madazli, S. Uludag, H. Uzun, and S. Kaya. 2004. Plasma malondialdehyde, superoxide dismutase, sE-selectin, fibronectin, endothelin-1 and nitric oxide levels in women with preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 113: 21-25.
33. Epstein, B. J., and S. Anderson. 2009. Endothelin receptor antagonists as antihypertensives: the next frontier. Expert Rev. Cardiovasc. Ther. 7: 675-687.
34. Zhou, C. C., Y. Zhang, R. A. Irani, H. Zhang, T. Mi, E. J. Popek, M. J. Hicks, S. M. Ramin, R. E. Kellems, and Y. Xia. 2008. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 14: 855-862.
35. Irani, R. A., Y. Zhang, S. C. Blackwell, C. C. Zhou, S. M. Ramin, R. E. Kellems, and Y. Xia. 2009. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J. Exp. Med. 206: 2809-2822.
36. Lund, A. K., M. B. Goens, B. A. Nuñez, and M. K. Walker. 2006. Characterizing the role of endothelin-1 in the progression of cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice. Toxicol. Appl. Pharmacol. 212: 127-135.
37. Liang, B., Z. Song, B. Wu, D. Gardner, D. Shealy, X. Y. Song, and P. H. Wooley. 2009. Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis. J. Inflamm. (Lond.) 6: 10.
38. Zhou, C. C., S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, C. Sun, A. Ahmed, R. E. Kellems, and Y. Xia. 2007. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 100: 88-95.
39. Sabaa, N., L. de Franceschi, P. Bonnin, Y. Castier, G. Malpeli, H. Debbabi, A. Galaup, M. Maier-Redelsperger, S. Vandermeersch, A. Scarpa, et al. 2008. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest. 118: 1924-1933.
40. Zhou, C. C., R. A. Irani, Y. Zhang, S. C. Blackwell, T. Mi, J. Wen, H. Shelat, Y. J. Geng, S. M. Ramin, R. E. Kellems, and Y. Xia. 2010. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121: 436-444.
41. Wang, W., H. Yen, C. H. Chen, R. Soni, N. Jasani, G. Sylvestre, and S. E. Reznik. 2008. The endothelin-converting enzyme-1/endothelin-1 pathway plays a critical role in inflammation-associated premature delivery in a mouse model. [Published erratum appears in 2009 Am. J. Pathol. 174: 1120.] Am. J. Pathol. 173: 1077-1084.
42. Attinà, T., R. Camidge, D. E. Newby, and D. J. Webb. 2005. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91: 825-831.
43. Granger, J. P. 2003. Endothelin. Am. J. Physiol. 285: R298-R301.
44. Conrad, K. P., T. M. Miles, and D. F. Benyo. 1998. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am. J. Reprod. Immunol. 40: 102-111.
45. Levine, R. J., C. Lam, C. Qian, K. F. Yu, S. E. Maynard, B. P. Sachs, B. M. Sibai, F. H. Epstein, R. Romero, R. Thadhani, S. A. Karumanchi; CPEP Study Group. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355: 992-1005.
46. Levine, R. J., S. E. Maynard, C. Qian, K. H. Lim, L. J. England, K. F. Yu, E. F. Schisterman, R. Thadhani, B. P. Sachs, F. H. Epstein, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350: 672-683.
47. Rajagopalan, S., J. B. Laursen, A. Borthayre, S. Kurz, J. Keiser, S. Haleen, A. Giaid, and D. G. Harrison. 1997. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 30: 29-34.
48. de Jong, C. L., G. A. Dekker, and B. M. Sibai. 1991. The renin-angiotensin-aldosterone system in preeclampsia. A review. Clin. Perinatol. 18: 683-711.
49. Shah, D. M. 2005. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am. J. Physiol. Renal Physiol. 288: F614-F625.
50. Wallukat, G., V. Homuth, T. Fischer, C. Lindschau, B. Horstkamp, A. Jüpner, E. Baur, E. Nissen, K. Vetter, D. Neichel, et al. 1999. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103: 945-952.
51. Schiffrin, E. L. 1999. State-of-the-Art lecture. Role of endothelin-1 in hypertension. Hypertension 34: 876-881.
52. LaMarca, B., M. Parrish, L. F. Ray, S. R. Murphy, L. Roberts, P. Glover, G. Wallukat, K. Wenzel, K. Cockrell, J. N. Martin, Jr., et al. 2009. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 54: 905-909.
53. Alexander, B. T., A. N. Rinewalt, K. L. Cockrell, M. B. Massey, W. A. Bennett, and J. P. Granger. 2001. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 37: 485-489.
54. Gilbert, J. S., M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger. 2008. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 294: H541-H550.
55. LaMarca, B. B., K. Cockrell, E. Sullivan, W. Bennett, and J. P. Granger. 2005. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46: 82-86.
56. Roberts, L., B. B. LaMarca, L. Fournier, J. Bain, K. Cockrell, and J. P. Granger. 2006. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 47: 615-618.
57. Hocher, B., C. Thöne-Reineke, P. Rohmeiss, F. Schmager, T. Slowinski, V. Burst, F. Siegmund, T. Quertermous, C. Bauer, H. H. Neumayer, et al. 1997. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 99: 1380-1389.
58. Gómez-Garre, D., R. Largo, X. H. Liu, S. Gutierrez, M. J. López-Armada, I. Palacios, and J. Egido. 1996. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 50: 962-972. (Pubitemid 26302686)
59. Nakamura, T., I. Ebihara, M. Fukui, Y. Tomino, and H. Koide. 1995. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899.
60. Ortmann, J., P. C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R. Hofmann-Lehmann, E. Haas, B. Frank, L. M. Terraciano, and M. Barton. 2005. Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem. Biophys. Res. Commun. 334: 689-695.
61. Silver, R. M., B. Schwinzer, and J. A. McGregor. 1993. Interleukin-6 levels in amniotic fluid in normal and abnormal pregnancies: preeclampsia, small-for-gestational-age fetus, and premature labor. Am. J. Obstet. Gynecol. 169: 1101-1105.
62. Nakabayashi, M., M. Sakura, Y. Takeda, and K. Sato. 1998. Elevated IL-6 in midtrimester amniotic fluid is involved with the onset of preeclampsia. Am. J. Reprod. Immunol. 39: 329-334.
63. Munno, I., L. M. Chiechi, G. Lacedra, C. Berardesca, C. Patimo, L. Marcuccio, P. Nardelli, and P. Loizzi. 1999. Evaluation of nonspecific immunity and plasma levels of interferon-gamma, interleukin-6 and tumor necrosis factor-alpha in preeclampsia. Immunopharmacol. Immunotoxicol. 21: 551-564.
64. Gadonski, G., B. B. LaMarca, E. Sullivan, W. Bennett, D. Chandler, and J. P. Granger. 2006. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension 48: 711-716.
65. Girardi, G., D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon. 2006. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203: 2165-2175.
66. Salmon, J. E., and G. Girardi. 2008. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J. Reprod. Immunol. 77: 51-56.
67. Fliser, D., K. Buchholz, H. Haller; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. 2004. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107.
68. Manabe, S., T. Okura, S. Watanabe, T. Fukuoka, and J. Higaki. 2005. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J. Cardiovasc. Pharmacol. 46: 735-739.
69. Vázquez-Oliva, G., J. M. Fernández-Real, A. Zamora, M. Vilaseca, and L. Badimón. 2005. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J. Hum. Hypertens. 19: 457-462.
70. Orshal, J. M., and R. A. Khalil. 2004. Interleukin-6 impairs endotheliumdependent NO-cGMP-mediated relaxation and enhances contraction in systemic vessels of pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286: R1013-R1023.
71. Coles, B., C. A. Fielding, S. Rose-John, J. Scheller, S. A. Jones, and V. B. O'Donnell. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 171: 315-325.
72. Lee, D. L., L. C. Sturgis, H. Labazi, J. B. Osborne, Jr., C. Fleming, J. S. Pollock, M. Manhiani, J. D. Imig, and M. W. Brands. 2006. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am. J. Physiol. Heart Circ. Physiol. 290: H935-H940.
73. Agarwal, R., A. Loganath, A. C. Roy, Y. C. Wong, C. Lindoff, and S. C. Ng. 2000. Increased expression of interleukin 6 in term compared to the first trimester human placental villi. Horm. Metab. Res. 32: 164-168.
74. Bowen, R. S., Y. Gu, Y. Zhang, D. F. Lewis, and Y. Wang. 2005. Hypoxia promotes interleukin-6 and -8 but reduces interleukin-10 production by placental trophoblast cells from preeclamptic pregnancies. J. Soc. Gynecol. Investig. 12: 428-432.
75. Jones, H. N., T. Jansson, and T. L. Powell. 2009. IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2. Am. J. Physiol. Cell Physiol. 297: C1228-C1235.
76. Langer, B., M. Grima, C. Coquard, A. M. Bader, G. Schlaeder, and J. L. Imbs. 1998. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet. Gynecol. 91: 196-202.
77. Battistini, B., N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan. 2006. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp. Biol. Med. (Maywood) 231: 653-695.
78. Kohan, D. E. 2010. Endothelin, hypertension and chronic kidney disease: new insights. Curr. Opin. Nephrol. Hypertens. 19: 134-139.